AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

OCS · NASDAQ · Biotechnology

Oculis

Develops investigational therapies for neuro-ophthalmology and dry eye disease.

$12.21

After-hours close−0.01 (−0.08%)

At close$12.22(−1.69%)

Something off on this page? Send us feedback.

Profile

Oculis Holding AGOCSHealth Care

Develops investigational ophthalmic and neuro-ophthalmic therapies, with development focused on Privosegtor and Licaminlimab. Its programs build on OPTIREACH eye-drop formulation research and licensed assets.

Investigational eye-care pipeline includes Privosegtor for neuro-ophthalmic programs and Licaminlimab for ocular inflammation and dry eye disease. Both are registrational programs following the 2026 change in development focus.

OPTIREACH formulation research was designed to enable eye drops to reach the back of the eye. The portfolio also reflects licenses for Licaminlimab and Privosegtor from Novartis and Accure Therapeutics.

Headquartered in Switzerland, operations span the United States and Iceland. All named programs remain investigational, and the company will not pursue an FDA filing for OCS-01 in diabetic macular edema after its Phase 3 trials missed their primary endpoint.

Company facts

CEORiad Sherif, M.D.

ListedMar 3, 2023

ExchangeNASDAQ

HeadquartersZug, Switzerland

CountrySwitzerland

Employees60

CIK0001953530

ISINCH1242303498

Key statistics

Market cap$698.0M

EPS (ttm)−$1.73

P/E (ttm)−7.06

ROE-42.9%

P/B2.76

P/S2,324.24

Dividend yield—

Beta1.01vs XLV 0.26

Year to date −38.9% · Average volume (30d) 257.6K

Analysts

Price target, next 12 months$38.00+211.2%Median of 9 analysts · vs the Aug 28 close

ConsensusBuy9 of 9 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $12.21

High$50.00+309.5%

Median$38.00+211.2%

Low$26.00+112.9%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Rating	Prior target	Target
Jun 1, 2026	Robert W. Baird	Target		$37	$38
Jun 1, 2026	Guggenheim	Reiterate	Buy	$75	$45
Jun 1, 2026	Needham	Reiterate	Buy		$38
Jun 1, 2026	H.C. Wainwright	Target		$47	$26
May 20, 2026	Guggenheim	Target			$75

Earnings

EPS

Estimate−$0.48

ReportedDue Nov 5, 2026

Revenue

Estimate$268.5K

ReportedDue Nov 5, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 6, 2026Q2 FY26	−$0.48	−$0.20	+58.3%	$216.8K	$371.1K	+71.2%	+2.42%
May 11, 2026Q1 FY26	−$0.49	−$0.63	−28.6%	$253.8K	$250.3K	−1.4%	−6.86%
Mar 3, 2026Q4 FY25	−$0.48	−$0.51	−6.7%	$142.9K	$518.4K	+262.8%	+0.54%
Nov 10, 2025Q3 FY25	−$0.50	−$0.40	+20.0%	$136.9K	$305.5K	+123.2%	−0.10%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$0	$322.6K	$300.3K	$0	$0	$0
Gross profit	$0	−$18.1M	$300.3K	$0	−$194.6K	$0
Operating income	−$24.7M	−$25.7M	−$25.1M	−$25.8M	−$27.7M	−$29.1M
Net income	−$41.0M	−$31.4M	−$20.8M	−$28.8M	−$36.5M	−$12.3M
Diluted EPS	−$0.85	−$0.61	−$0.40	−$0.52	−$0.62	−$0.20
Gross margin	—	-5,612.3%	100.0%	—	—	—
Operating margin	—	-7,957.1%	-8,352.3%	—	—	—

Fiscal years (4-quarter sums)FY22 $306.5K · FY23 $0 · FY24 $0 · FY25 $622.9K

Balance sheet, Jun 30, 2026Cash & short-term investments $9.9K · Total debt $3.1M · Total assets $309.4M · Shareholders' equity $271.1M

Dividends

No dividends on record.

Ownership

Institutions 35.20%Insiders —

Shares outstanding 57.17M · Float 37.03M · 64.8% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
LSP 7 Cooperatieve U.A.	6.95M	11.80%	13G	Apr 29, 2026
Eqt Fund Management S.A R.L.	5.90M	10.32%	13F	May 14, 2026
Abrdn PLC	1.75M	3.06%	13F	Apr 29, 2026
Pivotal Bioventure Partners Investment Advisor LLC	1.68M	2.94%	13F	May 14, 2026
Wellington Management Group LLP	1.35M	2.35%	13F	May 15, 2026

Insider tradesForm 4

Nothing filed in the last 12 months.